Bivalent COVID-19 booster safety profile consistent with monovalent vaccine
January 17th 2023The Centers for Disease Control and Prevention has provided an updated safety profile on the bivalent COVID-19 booster vaccine in children aged 5 to 11 years, showing similar adverse events to the monovalent vaccine.
ADHD medications do not significantly increase cardiovascular disease risk
January 16th 2023A recent study found that the risk of cardiovascular diseases was not significantly greater in patients taking medications for attention-deficit/hyperactivity disorder (ADHD), but investigators were not able to rule out a mild risk increase.
Prenatal benzodiazepine exposure not directly associated with ASD and ADHD
January 11th 2023A recent study found that while children exposed to benzodiazepine during pregnancy had a greater risk of developing autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD), siblings without exposure saw similar risks of neurodevelopmental disorders.